Brivaracetam

DB05541ApprovedInvestigationalSmall moleculeAnticonvulsantsMiscellaneous Anticonvulsants

Brivaracetam is an anticonvulsant used for the treatment of partial-onset seizures that functions by binding to synaptic vesicle glycoprotein 2A (SV2A) in the brain. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam.

Chemical structure of Brivaracetam
Mechanism
Curator reviewed
Primary indication
Used as adjunctive therapy for partial-onset seizures in patients 16 years of age or older.Curator reviewed · 1 structured indication
Formula / weight
C11H20N2O2 · 212.2887 g/mol (avg)
First approval
Canada, 2016 · United States, 2016 · European Union, 2016
Code names
UCB-34714
Brand names
  • Briviact

Resolves to

Compound
UNIIU863JGG2IACAS357336-20-0ChEMBLCHEMBL607400ChEBI133013PubChem9837243KEGGD08879
Clinical / RWD
RxNorm1739745ATCN03AX23PharmGKBPA166153491
Structure
InChIKeyMSYKRHVOOPPJKU-BDAKNGLRSA-NSMILESCCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1
Targets
Q7L0J3SV2A

What you can answer from here — as of September 23, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
1,664Drug interactionsStructured to mechanism, not free text
Sign in
30Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
171Marketed productsAcross 6 countries and 23 labellers
Sign in
1ATC codeIncluding every combination product, plus 14 drug categories
Sign in
15+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Brivaracetam, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In